Presented at the 2011 American Academy of Allergy.

These data, presented at the 2011 American Academy of Allergy, Immunology and Asthma annual meeting, derived from two recent trials of Hizentra, one performed in the usa and one in the European Union, and aimed showing the relationship between subcutaneous IgG dosage and clinical outcomes. Earlier studies show that higher immunoglobulin G doses by intravenous infusion bring about higher serum IgG and therefore fewer infections. Hizentra is indicated for the treatment of sufferers with PI read the description .2 mg/kg bw SCIg . Efficacy was assessed over 28 or 54 weeks. Related StoriesAnxiety connected with poor asthma outcomesResearchers discover proteins that plays crucial part in development of allergic airway inflammationFour types of gut bacteria can guard infants from asthmaAlthough both studies demonstrated clear evidence of effectiveness with zero severe serious bacterial attacks , patients on the higher of the two dosages of SCIg experienced a lesser rate of infection and fewer times missed from school/work .

For the study, the researchers analyzed 37 sufferers with 43 known or suspected extracranial ICA stenoses who underwent MDCTA and vascular ultrasound. The researchers discovered that exceptional visualization of vessels was attained on MD-CTA in every cases. Of the 43 stenoses, 28 were closed between 70-80 percent, 10 were closed between 80-90 percent and all had been properly identified with MD-CTA and vascular ultrasound. Related StoriesCombination of ultrasound and mammography detects additional cancers in Japanese womenSonaCare Medical's Sonablate 450 focused ultrasound program receives FDA authorization for ablation of prostate tissueUltrasound treatment boosts skin healing among diabetics and the elderlyAccording to the researchers, it is important to be able to identify high-quality ICA stenosis to program the appropriate therapy and surgery.